LINC02191: A Potential Drug Target and Biomarker (G105371146)

Target Name: LINC02191

NCBI ID: G105371146

LINC02191

Other Name(s): LINC02191 variant X2 | long intergenic non-protein coding RNA 2191 | Long intergenic non-protein coding RNA 2191, transcript variant X2

LINC02191: A Potential Drug Target and Biomarker

LINC02191 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. It is a non-coding RNA molecule that is located on chromosome 6p12 and has been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and invasion.

One of the key features of LINC02191 is its ability to interact with several different proteins, including the transcription factor, NF-kappa-B, and the protein, PDGF. This interaction between LINC02191 and these proteins makes it a promising target for drugs that are designed to modulate the activity of these transcription factors.

In addition to its potential as a drug target, LINC02191 has also been identified as a potential biomarker for several diseases, including cancer. The expression of LINC02191 has been shown to be elevated in the tissues and fluids of individuals with various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that LINC02191 may be a useful biomarker for the diagnosis and treatment of these cancers.

The identification of LINC02191 as a potential drug target and biomarker has important implications for the development of new treatments for a variety of diseases. By targeting the transcription factor, PDGF, and other proteins that are involved in cell signaling pathways, LINC02191 may be able to modulate the activity of these molecules and lead to the inhibition of cell proliferation and the regression of cancer tumors.

In addition to its potential as a drug target and biomarker, LINC02191 also has several potential therapeutic applications in other areas. For example, it has been shown to play a role in the regulation of cell adhesion, which is important for the development and maintenance of tissues and organs. LINC02191 may also be a useful target for the treatment of diseases that are characterized by the excessive production of cells, such as cancer.

In conclusion, LINC02191 is a promising drug target and biomarker for a variety of diseases. Its interaction with transcription factors, PDGF, and other proteins that are involved in cell signaling pathways makes it a good candidate for the development of new treatments for cancer and other diseases. Further research is needed to fully understand the role of LINC02191 in these diseases and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 2191

The "LINC02191 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02191 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets